Filtered By:
Condition: Bleeding
Management: Venture Capital
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Will Peregrine Data Be the Turning Point for Hypertension Therapy?
Ablative Solutions just made a significant contribution to the resurgence of renal denervation procedures for the treatment of uncontrolled hypertension. The Kalamazoo, MI-based company added to the treatment’s resurgence narrative by unveiling compelling data from the Peregrine Post-Market Clinical Trial.
The data reveal was during a late-breaking session at the 2019 Cardiovascular Research Technologies meeting in Washington D.C. last week.
The Post-Market Study is a European multicenter open-label trial that evaluated the safety and performance of the Peregrine System Infusion Catheter, which has CE mar...
Source: MDDI - March 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
